Galmed Pharma (GLMD) Updates on 'At-The-Market' Financing Program; Says ~$5M Raised
Get inside Wall Street with StreetInsider Premium. Claim your 2-week free trial here.
Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) announced that, to date, it has raised approximately $5.0 million under the Company's At-The-Market financing executed by Cantor Fitzgerald (the "ATM"). In total, to date the Company has issued 933,160 ordinary shares under the ATM at an average sale price of $5.11 per share.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- NQ Mobile (NQ) Enters LOI for Sale of FL Mobile, Showself and $100M Investment
- eBay (EBAY) Needs To Show Evidence Of Sustainable Turnaround Before Cantor Fitzgerald Can Become More Constructive
- Targa Resources (TRGP) to Offer 7M Shares of Common Stock
Create E-mail Alert Related CategoriesCorporate News, Equity Offerings
Related EntitiesCantor Fitzgerald
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!